On July 29, 2026, the FDA approved Gwyn Lo (norelgestromin/ethinyl estradiol patch, Viatris), a once-weekly combined hormonal contraceptive for women with a BMI under 30 who are good CHC candidates. It hits the market later this year.
Both hormones moved in opposite directions
Almost every write-up leads with the estrogen drop and stops there. That’s the miss.
Gwyn Lo is the same hormone combo as Xulane, just redosed. The estrogen went down by over 40% (from 35 to 20 mcg/day). But the progestin went up by nearly half. That progestin is norelgestromin, the active metabolite of norgestimate, so it’s the same class your patients on Ortho Tri-Cyclen already know. Those two hormones behave differently in the body, and a patient thinking about switching deserves both facts, not just the marketing-friendly one.
If she’s coming to you because of estrogenic side effects, the lower estrogen genuinely matters. But the higher progestin dose is a variable you don’t get to ignore.
Is it actually more effective? Maybe.
Here’s the honest answer: Approval rested on a single-arm trial with no comparator. The older 35 mcg patch has historically been cited far lower, but cross-trial comparison is unreliable (different populations, different eras, different methods), so the fair takeaway is simply this: efficacy hasn’t been shown to be equal or better than what she’s already on.
The VTE story hasn’t changed
This is the counseling landmine: “low-dose estrogen” does not mean lower clot risk.
Ethinyl estradiol activates clotting pathways in the liver no matter how it’s delivered, which is exactly why birth control patches have never earned the safety edge that menopausal estradiol patches get. The label reflects this. Nothing about the lower estrogen relaxes the usual rules:
- Boxed warning: smoking plus age over 35 is contraindicated.
- Indicated only for BMI under 30.
- All the standard CHC contraindications still apply (prior clots, migraine with aura, uncontrolled hypertension, breast cancer history, and the rest).
If a patient’s main worry is clot risk, this isn’t her answer. Progestin-only methods or the levonorgestrel IUD remain the evidence-based go-to.
On cycle control
Spotting and unscheduled bleeding declined over the year of the trial, as it typically does with most CHCs as the body adjusts. Whether the higher progestin dose contributes is unknown, and there was no comparator to test it against. So it’s a normal trend, not a proven edge. And since the trial was single-arm, the same caveat applies to tolerability overall: any “better tolerated than Xulane” claim is still theoretical until someone runs the head-to-head.
Bottom line
Gwyn Lo is a reasonable lower-estrogen weekly option for patients who like the patch and had estrogenic side effects on the old one. But it’s not “Xulane with less hormone”, it’s Xulane with less estrogen and more progestin, no proven efficacy edge, and no proven clot-risk advantage.
When that patient hands you her printout, the most useful thing you can do is finish the sentence the marketing left off: both numbers moved, only one made the headline.
Sources: FDA approval / Viatris (July 29, 2026); Gwyn Lo package insert; pivotal Phase 3 single-arm trial (NCT05139121).
